Compare Inovio Pharmaceuticals Inc (INO) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Financial Select Sector SPDR Fund — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $112.19M), while Financial Select Sector SPDR Fund trades at $54.69 (market cap $50.06B). The key difference: Financial Select Sector SPDR Fund is far larger — about 446.2× Inovio Pharmaceuticals Inc's market cap, and Financial Select Sector SPDR Fund is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| INO | XLF | |
|---|---|---|
Market Cap | $112.19M | $50.06B |
Volume | 3,201,278 | 47,464,120 |
Sector | Health | — |
52-Week High | $2.65 | $58.55 |
52-Week Low | $0.66 | $47.80 |
Typical Hold Time | 43 Days | 104 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
XLF trades at $54.48, up 1.36% with a bearish technical signal from moving averages. The ETF faces headwinds as financial stocks lag the S&P 500 by the widest margin since 1990 despite rising bank profits. Recent Fed stress test changes and interest rate hikes create both opportunities and challenges for financial sector performance.
The outlook remains cautious with technical indicators showing bearish momentum. Rising interest rates could benefit financial sector profitability, but regulatory uncertainty and market underperformance relative to broader indices present near-term risks for investors seeking financial sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
